Can 3 Questions Flag Depression? PHQ-3 Tested
In a study of more than 96,000 US adult participants, the PHQ-3 had 98% sensitivity and 76% specificity for predicting at least moderate or greater depressive symptoms.
Additionally, it was 'highly correlated' with the full PHQ-9 and noninferior to a recently validated 4-item version for effectiveness — and it yielded a sensitivity of more than 90% across all ages, races, and ethnicities.
Lead investigator Roy H. Perlis, MD, vice chair of research in the Department of Psychiatry at Mass General Brigham in Boston, said the team set out to identify the shortest version of the PHQ-9 that could still effectively screen for depression — and found that the PHQ-3 hit the 'sweet spot.'
'We let the data tell us what the constellation of symptoms are that best predict overall severity and how well they do at identifying depression. It's a way we might be able to get the maximum amount of information in the shortest amount of time,' Perlis told Medscape Medical News.
However, he noted that he's not yet ready to endorse the PHQ-3 for use in clinical practice.
'I want to see further studies in clinical settings. But I think we made a good start towards showing it did well in a big, general sample of US adults,' Perlis said.
The findings were published online on July 21 in JAMA Network Open .
Shorter Attention Spans
'The PHQ-9 was not intended as a tool to diagnose depression. It's just a way to start the conversation; and although it's not perfect, it is useful,' Perlis noted.
The original patient-reported PHQ screens for depression, anxiety, eating disorders, alcohol misuse, and somatization. Its 9-item depression scale (PHQ-9) became widely used to identify depression along with related symptoms such as fatigue and sleep disturbances.
However, the length of the questionnaire has become burdensome for some patients, particularly those who prefer using phone apps over printed forms. 'Faced with a long list of survey questions, some individuals may be tempted to speed through or to not respond at all,' the investigators wrote.
At the recent American Psychiatric Association (APA) annual meeting, clinicians in the audience at several sessions mentioned that their patients have been complaining that the PHQ-9 is too long and that they prefer data to be delivered in smaller 'chunks.'
Perlis said that attitude was a big motivator for the study. 'We're in an era where we have shorter attention spans and people want things very quickly,' he said.
'Personally, I would always rather have the PHQ-9. The question we were trying to answer was: Can we ask fewer questions if we don't have the time or the space to ask about nine [items] and do almost as well?' Perlis said.
The researchers assessed data from four waves of an online survey conducted from November 2023 to July 2024. In the first wave, they identified the optimal questionnaire items to be included.
The four waves had a total of 96,234 participants (57% women; mean age, 47.3 years). Of these, 68% were White, 13% were Black, 10% were Hispanic or Latino, 5% were Asian, and 4% were classified as 'other.'
In the full patient population, 26% had moderate or greater depressive symptoms, as measured by a PHQ-9 score ≥ 10.
Follow-up Is Key
After examining shortened versions of the PHQ-9 that ranged from including just one item up to eight items, the PHQ-3 with items 1 (interest), 2 (depressed mood), and 6 (self-esteem or failure) was deemed to be the 'optimal' version.
It had a sensitivity of 0.98 (95% CI, 0.97-0.98) and a specificity of 0.76 (95% CI, 0.75-0.76) for moderate or greater depressive symptoms.
Across all subgroups except participants aged 65 years or older, the sensitivity for the PHQ-3 was greater than 0.94. For that subgroup, it was 0.93.
The PHQ-3 was also noninferior to previously reported sensitivity and specificity of the PHQ-Depression-4 in the whole study group and in all subgroups.
The area under the receiver operating characteristic curve (AUROC) for predicting moderate or greater depressive symptoms was 0.83 for the PHQ-3. The AUROC for the PHQ-9 was 0.84.
'While a shortened scale cannot capture the full range of the PHQ-9, it may facilitate more widespread and efficient investigation of psychiatric symptoms in general population samples when participant burden and/or data collection expense must be minimized,' the investigators wrote.
Overall, Perlis said the PHQ-3 could be a possible first-step screening tool, with more questions added as needed.
'What's most important is that people are screening for depression and, if someone screens positive, that they're following up with a more comprehensive evaluation and offering treatment if it's indicated,' he said. 'It's really about figuring out who needs follow-up.'
Menu of Options?
In an accompanying editorial, Kurt Kroenke, MD, of Regenstrief Institute, Indianapolis, Indiana, noted that the study had 'numerous strengths,' including its large and diverse study population, as well as several limitations.
First, the criteria for calculating sensitivity and specificity did not include a structured psychiatric interview — the standard used in previous evaluations of the 2- and 4-item PHQs. In addition, because the researchers drew from a general population sample, future studies should focus on actual patients in both primary care and psychiatric settings, Kroenke suggested.
He noted that, in addition to the various shortened PHQs, the 2-item and 4-item versions of the Patient-Reported Outcomes Measurement Information System (PROMIS) have also demonstrated benefit.
'Clinicians and researchers looking for ultrashort depression measures now have a menu from which to choose, which is good since one size may not fit all purposes,' Kroenke wrote.
'Expanded use of brief screeners to increase detection of depression has the potential to decrease the burden of the most prevalent mental disorder worldwide,' he added.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
29 minutes ago
- Forbes
Novel Access Model For Sickle Cell Disease Gene Therapy Could Be Template
The Centers for Medicare and Medicaid Services announced in July that 33 states, the District of Columbia and Puerto Rico will join a new voluntary program intended to improve patient access to and lower costs for gene therapies targeting sickle cell disease. This was a Biden administration initiative, which the Trump administration decided to continue to implement. It ties payment for two novel gene therapies to positive clinical outcomes. This could make such treatments that cost millions be more widely accessible for patients. And if successful, it may serve as a template for future cell and gene therapy agreements. Medicaid, the joint federal and state program that provides health coverage to low-income individuals, is the main insurer for SCD patients. The Biden administration announced last year that the manufacturers of Lyfgenia and Casgevy had entered into agreements with CMS to participate in the Cell and Gene Therapy Access Model, which allows CMS to negotiate outcomes-based agreements on behalf of state Medicaid programs for cell and gene therapies, beginning with sickle cell disease treatments. Essentially this means that CMS will reimburse based on whether certain agreed-upon clinical thresholds are reached in patients. According to CMS, the participating states in the newly established access initiative represent about 84% of Medicaid beneficiaries with SCD. The program could contribute towards a sizable expansion of access to potentially transformative care in the form of two extraordinarily expensive gene therapies. The launch prices for Casgevy (exagamglogene autotemcel) and Lyfgenia (lovotibeglogene autotemcel) were $2.2 million and $3.1 million, respectively. SCD is a group of congenital red blood cell disorders, named sickle cell for their crescent shape. The condition affects millions of people worldwide. In the United States, approximately 100,000 individuals are living with the disease, which predominantly impacts people of sub-Saharan African descent. The disease alters the structure of hemoglobin, the molecule in red blood cells that delivers oxygen to organs and tissue throughout the body. As a consequence, this causes severe pain, anemia, organ damage and infections. Individuals with the disease have a shorter life expectancy, by more than 20 years on average. The most common sickle cell disorder type is sickle cell anemia. Besides pain medications to relieve symptoms as well as antibiotics to treat infections, hydroxyurea—a bone marrow suppressive agent that decreases red blood cell production—can be used to reduce the frequency of painful episodes. It has been in use since the 1980s. The Food and Drug Administration has approved several new therapeutics in the past ten years, but none are as promising as Lyfgenia and Casgevy. These two novel therapies can decrease or potentially eliminate pain crises in patients. Gene therapies such as Lyfgenia and Casgevy are administered in an inpatient hospital setting but are considered covered outpatient drugs because they're directly reimbursed and subject to standard, federally mandated Medicaid rebates. Manufacturers of the two treatments must also provide states with supplemental rebates (post-hoc discounts off of the list price) reflecting model-negotiated terms. In turn, states are obligated to implement an agreed-upon access policy for patients. According to CMS, there is also optional federal support of up to $9.55 million per state available to help with implementation of the arrangements, outreach and data tracking. In the cell and gene therapy space, science has generally outpaced commercialization. Access to very costly treatments is a challenge. Whether in the public or commercial sector, payers must find novel ways of paying for cell and gene therapies while generating evidence with respect to their real-world effectiveness and safety. Questions insurers must find answers to include: What are the health outcomes for patients in real-world settings? Do treatments fulfill the promise of a one-time cure for certain serious illnesses or disorders? Are there particular safety concerns that appear in real-world settings? Are side effects manageable? Coordinating evidence gathering as well as contracts across state Medicaid agencies is likely to yield a more efficient process while improving access for a substantial majority of SCD sufferers nationwide. It's not just SCD gene therapies that confront a formidable set of barriers to access. All cell and gene therapy manufacturers face a challenging environment. The regulatory hurdles are enormous to begin with, but manufacturing challenges following approval are considerable, too. Furthermore, patient preparation, side effect and adverse event profiles can be intolerable. This can deter patients from signing up to initiate treatment. On top of all of this, payers concerned about the high per unit costs often impose coverage restrictions, as the Tufts Center for the Evaluation of Value and Risk in Health describes. Nonetheless, gene therapies in particular hold the promise of delivering groundbreaking improvements in health outcomes across multiple disease areas. Therefore, overcoming obstacles to optimal patient access is crucial. If successful, the SCD model being experimented with could serve as a blueprint for other cell and gene therapies that have faced considerable barriers with respect to patient access.
Yahoo
an hour ago
- Yahoo
Check Your Kitchen—Experts Say These 10 Foods Contain The Most Microplastics
"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." Microplastics are found in many everyday foods like rice, tea, bottled water, and seafood. Early research suggests microplastics may contribute to health issues like oxidative stress, organ dysfunction, and metabolic or immune disruptions, though more studies are needed. Experts recommend reducing exposure by choosing loose-leaf tea, rinsing rice, avoiding plastic bottles, and opting for minimally processed or non-plastic-packaged foods. Almost everything we eat these days is transported or stored in plastic, and we've all zapped leftovers in the microwave in plastic containers. But you may not have realized that microplastics actually can be found inside the foods we eat. It's actually not a new topic. "Research into the effects of microplastic consumption has been ongoing for several decades," says Stephani Johnson, D.C.N., R.D.N., adjunct professor, Department of Clinical and Preventive Nutrition Sciences at Rutgers, The State University of New Jersey. "However, there is still much to learn regarding the average levels of human exposure, how long microplastics remain in the body, and their associated health consequences. What is currently known is that microplastics are ubiquitous in the environment, making complete avoidance virtually impossible." Studies have found microplastics throughout the human body, including in the brain, heart, colon, placenta, and more. "We are what we eat, and we are eating and being exposed to plastics in our food," Nicholas Mallos, vice president of conservation, ocean plastics, at the Ocean Conservancy, and co-author of a recent study on microplastics in commonly-consumed proteins. "While we need more research to know what exposure levels of plastics are causing human health problems, we should be concerned." What Are The Health Consequences Of Consuming Microplastics? Emerging evidence suggests that potential harm may depend on several factors, including the amount consumed, as well as the type, size, and shape of the microplastic particles. "At the cellular level, studies have shown that microplastics can contribute to oxidative stress, DNA damage, organ dysfunction, and disruptions in metabolic, reproductive, and immune functions, as well as neurodevelopmental toxicity," Johnson says. Unfortunately, there is still much we don't know about microplastics in food. "Our study demonstrates the need for further research to better understand microplastics in the most commonly consumed foods, including precisely where these microplastics are coming from and the potential human health risks," Mallos says. Ahead, the foods that research has found to contain a measurable amount of microplastics: Tea Many commercial tea bags are made with polypropylene, a type of plastic used to seal the bags and maintain their shape. "When steeped in hot water, these bags can release microplastics into the tea. To avoid potential ingestion of microplastics, using loose leaf tea with a stainless steel or other non-plastic tea infuser is a safer and more sustainable alternative," Johnson says. Rice "Studies have shown that rice can contain relatively high levels of microplastics, likely due to contamination of soil and irrigation water," Johnson says. Rinsing rice thoroughly before cooking has been found to reduce its microplastic content by approximately 20–40%. Ultra-Processed Foods There's evidence that food processing is a likely source of microplastic contamination. Research has found that highly-processed protein products, such as chicken nuggets, tofu, and plant-based burgers, contain significantly more microplastics per gram than minimally processed products, such as wild Alaska pollock and raw chicken breast, Mallos says. Bottled Water When exposed to heat—such as being left in a hot car—or subjected to physical stress, like squeezing, plastic water bottles can release microplastics into the water. "Among various types, single-use plastic bottles tend to release the highest amounts of microplastics, followed by reusable plastic bottles," Johnson says. "In contrast, stainless steel and glass bottles do not degrade or leach microplastics, making them a safer and more sustainable choice for drinking water." Salt Believe it or not, even salt—a naturally occurring mineral—isn't safe from microplastics. Research has found that salt can contain large amounts of microplastics, reflecting the broader problem of environmental pollution. Himalayan pink salt contains the greatest amounts, followed by black salt and sea salt, Johnson says. Fruits & Vegetables "Due to widespread environmental contamination, fruits and vegetables can contain measurable amounts of microplastics," Johnson says. Some types of produce are more susceptible than others, like root vegetables (such as carrots, potatoes, and beets), because they absorb microplastics from contaminated soil and rainwater through their root systems. But all types of plants can absorb microplastics through their roots. Honey Even honey may be contaminated by microplastics, which is also a concern due to widespread environmental contamination, Johnson says. Plant-Based Foods In the study co-authored by Mallos, microplastic particles were found in tofu, plant-based nuggets, plant-based fish sticks, and plant-based ground beef. Fresh Seafood Microplastics in the ocean accumulate in fish and shellfish, ultimately impacting humans, who consume seafood containing these particles, Johnson says. Bottom-feeding species, such as clams, mussels, oysters, catfish, halibut, flounder, and cod, tend to have higher concentrations of microplastics compared to other marine organisms. Processed Seafood Processed seafood fares no better. Research shows breaded shrimp, pollock fish sticks, and shrimp also contain microplastics, Mallos says. You Might Also Like Insanely Easy Weeknight Dinners To Try This Week 29 Insanely Delicious Vodka Cocktails Solve the daily Crossword
Yahoo
an hour ago
- Yahoo
SpaceX delivers four astronauts to the International Space Station just 15 hours after launch
CAPE CANAVERAL, Fla. (AP) — SpaceX delivered a fresh crew to the International Space Station on Saturday, making the trip in a quick 15 hours. The four U.S., Russian and Japanese astronauts pulled up in their SpaceX capsule after launching from NASA's Kennedy Space Center. They will spend at least six months at the orbiting lab, swapping places with colleagues up there since March. SpaceX will bring those four back as early as Wednesday. Moving in are NASA's Zena Cardman and Mike Fincke, Japan's Kimiya Yui and Russia's Oleg Platonov — each of whom had been originally assigned to other missions. Cardman and another astronaut were pulled from a SpaceX flight last year to make room for NASA's two stuck astronauts, Boeing Starliner test pilots Butch Wilmore and Suni Williams, whose space station stay went from one week to more than nine months. Fincke and Yui had been training for the next Starliner mission. But with Starliner grounded by thruster and other problems until 2026, the two switched to SpaceX. Platonov was bumped from the Soyuz launch lineup a couple of years ago because of an undisclosed illness. Their arrival temporarily puts the space station population at 11. While their taxi flight was speedy by U.S. standards, the Russians hold the record for the fastest trip to the space station — a lightning-fast three hours. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content. Solve the daily Crossword
